Association of Nirmatrelvir/Ritonavir Treatment and COVID-19-Neutralizing Antibody Titers in a Longitudinal Health Care Worker Cohort
Authors:
Open Access
- 1 February 2024
- journal article
- research article
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 11 (2) , ofad625
Abstract
Nirmatrelvir/ritonavir (NMV/r) is used for the treatment of coronavirus disease 2019 (COVID-19) infection. However, rebound COVID-19 infections can occur after taking NMV/r. We examined neutralizing antibodies to the severe acute respiratory syndrome coronavirus 2 spike protein before and after infection in people who did and did not take NMV/r to determine if NMV/r impedes the humoral immune response.Keywords
This publication has 8 references indexed in Scilit:
- Correlates of Protection, Thresholds of Protection, and Immunobridging among Persons with SARS-CoV-2 InfectionEmerging Infectious Diseases, 2023
- Clinical, Virologic, and Immunologic Evaluation of Symptomatic Coronavirus Disease 2019 Rebound Following Nirmatrelvir/Ritonavir TreatmentClinical Infectious Diseases, 2022
- Rebound of SARS-CoV-2 Infection after Nirmatrelvir–Ritonavir TreatmentNew England Journal of Medicine, 2022
- From Positive to Negative to Positive Again—The Mystery of Why COVID-19 Rebounds in Some Patients Who Take PaxlovidJAMA, 2022
- Characterization of Virologic Rebound Following Nirmatrelvir-Ritonavir Treatment for Coronavirus Disease 2019 (COVID-19)Clinical Infectious Diseases, 2022
- Association of Frailty, Age, and Biological Sex With Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Vaccine–Induced Immunity in Older AdultsClinical Infectious Diseases, 2022
- Impact of Age and Sex on Antibody Response Following the Second Dose of COVID-19 BNT162b2 mRNA Vaccine in Greek Healthcare WorkersMicroorganisms, 2021
- The host immune response in respiratory virus infection: balancing virus clearance and immunopathologySeminars in Immunopathology, 2016